BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma

Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development and progression of those melanoma carrying the V600E BRAF mutation, but there’s a subset of such patients who do not respond to the therapy. Various mechanisms of drug resistance have been proposed which inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiappetta, Caterina, Proietti, Ilaria, Soccodato, Valentina, Puggioni, Chiara, Zaralli, Roberto, Pacini, Luca, Porta, Natale, Skroza, Nevena, Petrozza, Vincenzo, Potenza, Concetta, Della Rocca, Carlo, Di Cristofano, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482453/
https://www.ncbi.nlm.nih.gov/pubmed/24710085
http://dx.doi.org/10.1097/PAI.0000000000000071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482453/
https://www.ncbi.nlm.nih.gov/pubmed/24710085
http://dx.doi.org/10.1097/PAI.0000000000000071

Ejemplares similares